Secunderabad Chronicle

Prostate Cancer Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Prostate Cancer Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
19:04 2023
Prostate Cancer Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Prostate Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including Prostate Cancer clinical trials and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Prostate Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Prostate Cancer clinical trial studies, Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from Prostate Cancer Pipeline Report

  • DelveInsight’s Prostate Cancer Pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer.
  • Key companies dedicated to advance the Prostate cancer drug pipeline are Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics and several others. 
  • Promising Prostate Cancer Pipeline Therapies such as P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others
  • The Prostate Cancer companies and academics are working to assess challenges and seek opportunities that could influence Prostate Cancer R&D. The Prostate Cancer pipeline therapies under development are focused on novel approaches to treat/improve Prostate Cancer.

 

To explore more information on the latest breakthroughs in the Prostate Cancer Pipeline treatment landscape of the report, click here @ Prostate Cancer Pipeline Outlook

 

Recent Developmental Activities in the Prostate Cancer Treatment Landscape

  • Vaccitech is currently developing ChAdOx1-MVA 5T4 vaccine (VTP-008). This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody.
  • Ultimovacs has started the clinical evaluation of Novel TET Tetanus-Epitope Targeting (TET)-platform based TENDU Vaccine for the treatment of Prostate cancer.
  • In October 2020, Foresee Pharmaceuticals announced that 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug Administration (FDA).
  • Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries). U.S Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix on December 18, 2020, for the treatment of adult patients with advanced prostate cancer.

 

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with Prostate Cancer in their lifetime. This year, nearly 250,000 men will be diagnosed with Prostate Cancer. Prostate Cancer cells can spread by breaking away from a prostate tumor. They can travel through blood vessels or lymph nodes to reach other parts of the body. After spreading, cancer cells may attach to other tissues and grow to form new tumors, causing damage where they land.

 

Request a sample and discover the recent advances in Prostate Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Prostate Cancer Treatment Landscape

 

Prostate Cancer Emerging Drugs Profile

Pembrolizumab: Merck & Co

Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 3 stage of development to treat Prostate Cancer.

 

Talazoparib: Pfizer

Talazoparib is an inhibitor of PARP enzymes, which play a role in DNA repair. Preclinical studies suggest that talazoparib may work by blocking PARP enzyme activity and trapping PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. Talazoparib anti-tumor activity also was observed in mouse models of human breast cancer that expressed mutated or non-mutated BRCA1/2.

 

ODM-208: Orion

ODM 208, an orally bioavailable, non-steroid selective inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme), is being developed by Orion. Steroid hormones stimulate the growth of hormonally regulated cancers, such as most prostate and breast cancers. Hormonal treatments are highly effective, but drug resistance will often eventually emerge and cancer will start growing again. The molecule (ODM-208) has shown antitumor activity. It has potential efficacy also for those cancers that have become resistant to the standard hormonal treatments. Currently, it is in phase 2 stage of development to treat Prostate Cancer.

 

ZEN 3694: Zenith Epigenetics

The company’s lead product, ZEN-3694, a BET inhibitor, in combination with enzalutamide, is in a Phase 2 randomized clinical trial for treatment of metastatic castration resistant Prostate Cancer (mCRPC) in patients that have progressed on an androgen receptor signaling inhibitor.

 

EPI-7386: ESSA Pharma

EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Phase 1 clinical trial (NCT04421222) in men with metastatic castration-resistant Prostate Cancer (“”mCRPC””) whose tumors have progressed on current standard-of-care therapies. The Phase I clinical trial of EPI-7386 began in Q3 of 2020 following FDA allowance of the IND and Health Canada acceptance. The U.S. FDA has granted Fast Track designation to EPI-7386 for the treatment of adult male patients with mCRPC resistant to standard-of-care treatment. ESSA retains all rights to EPI-7386 worldwide.

 

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for Prostate Cancer. The companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

 

For further information, refer to the detailed Prostate Cancer Unmet Needs, Prostate Cancer Market Drivers, and Market Barriers, click here for Prostate Cancer Ongoing Clinical Trial Analysis

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage- Global
  • Prostate Cancer Companies- Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics, and others.
  • Prostate Cancer Pipeline Therapies- P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others.
  • Prostate Cancer Pipeline Segmentation: Phases, Product Type, Mechanism of action, Route of administration, Molecule Type

 

Dive deep into rich insights for drugs for Prostate Cancer Market Drivers and Prostate Cancer Market Barriers, click here @ Prostate Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Prostate Cancer Executive Summary
  3. Prostate Cancer: Overview
  4. Prostate Cancer Pipeline Therapeutics
  5. Prostate Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Pembrolizumab: Merck & Co
  8. Drug profiles in the detailed report….
  9. Mid Stage Products (Phase II)
  10. ODM-208: Orion Pharma
  11. Drug profiles in the detailed report….
  12. Early Stage Products (Phase I)
  13. EPI 7386: ESSA Pharma
  14. Drug profiles in the detailed report….
  15. Preclinical and Discovery Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…
  18. Inactive Products
  19. Prostate Cancer Key Companies
  20. Prostate Cancer Key Products
  21. Prostate Cancer- Unmet Needs
  22. Prostate Cancer- Market Drivers and Barriers
  23. Prostate Cancer- Future Perspectives and Conclusion
  24. Prostate Cancer Analyst Views
  25. Prostate Cancer Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Prostate Cancer Mergers and acquisitions, Prostate Cancer Licensing Activities @ Prostate Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Related Articles